Prevalence of Globo H - a novel glycotarget - and association to clinicopathological features in human breast cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032596

Enrollment

Registered

2025-03-10

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer (luminal B1/B2, Her2/neu amplified)

Interventions

Group 1: Non-interventional, retrospective biobank study The expression of Globo H will be analysed on tissue sections by immunohistochemical stainings and then correlated to clinical parameters (stag

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Breast cancer (luminal B1/B2 or Her2/neu amplified)

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
prevalence of Globo H expression in human breast cancer	—

Countries

Germany

Contacts

Public ContactMatthias Ocker

Tacalyx GmbH

ocker@tacalyx.com+493040723710

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026